A Randomized, Double-Blind, Controlled Withdrawal Trial in Crohn’s Disease Patients in Long-term Remission on Azathioprine
- 1 June 2005
- journal article
- clinical trial
- Published by Elsevier BV in Gastroenterology
- Vol. 128 (7), 1812-1818
- https://doi.org/10.1053/j.gastro.2005.03.031
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Long‐term risk of malignancy after treatment of inflammatory bowel disease with azathioprineAlimentary Pharmacology & Therapeutics, 2002
- The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year reviewGut, 2002
- A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's diseaseGastroenterology, 2000
- Epstein-Barr Virus–Positive Primary Gastrointestinal Hodgkin's DiseaseThe American Journal of Surgical Pathology, 2000
- Malignant Neoplasms Subsequent to Treatment of Inflammatory Bowel Disease With 6-MercaptopurineAmerican Journal Of Gastroenterology, 1999
- Optimum Duration of Treatment With 6-Mercaptopurine for Crohn's DiseaseAmerican Journal Of Gastroenterology, 1999
- Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurineThe Lancet, 1996
- A controlled double blind study of azathioprine in the management of Crohn's disease.Gut, 1995
- Long-term neoplasia risk after azathioprine treatment in inflammatory bowel diseaseThe Lancet, 1994
- Treatment of Crohn's Disease with 6-MercaptopurineNew England Journal of Medicine, 1980